Regarding the association of CBF rearrangement in BP-CML, it is important to stress that ACAs can be observed in 3–7% of patients with CML at the time of diagnosis, but they are more frequent at disease progression to BP (60–80%) [38,39]. This evidence concerns the gene CEBPZ and chronic myelogenous leukemia, BCR-ABL1 positive.